<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Dalamaga, M</style></author><author><style face="normal" font="default" size="100%">Koumaki, V</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">&lt;span style=&quot;font-size: 12.0pt; font-family: 'Times New Roman',serif; mso-fareast-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EL; mso-bidi-language: AR-SA;&quot;&gt;Adiponectin &amp;amp; Cancer: &lt;em&gt;deep insight&lt;/em&gt;.&lt;/span&gt;</style></title><secondary-title><style face="normal" font="default" size="100%">Atlas Genet Cytogenet Oncol Haematol.</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year></dates><volume><style face="normal" font="default" size="100%">18</style></volume><pages><style face="normal" font="default" size="100%">361-367</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;A growing body of evidence suggests that adiponectin presents anti-neoplastic effects via two mechanisms. First, adiponectin can act directly on tumor cells by enhancing receptor-mediated signaling pathways. Secondly, adiponectin may act indirectly by regulating inflammatory responses, influencing cancer angiogenesis and regulating insulin sensitivity at the target tissue site&lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">5</style></issue></record></records></xml>